Top Industry Leaders in the Hemifacial Spasm Market
Latest Hemifacial Spasm Companies Updates:
Medtronic (US): Acquired Intersect ENT, Inc. (US) in August 2023, strengthening its portfolio of interventional ENT devices and potentially including advancements in facial nerve procedures relevant to HFS treatment.
Allergan (US): Featured its BOTOX® cosmetic and therapeutic applications, including for HFS management, in its recent investor presentation, highlighting the broader reach of botulinum toxin solutions.
Satiety Therapeutics, Inc. (US): Received FDA Fast Track designation for its STX-100 botulinum toxin A drug for HFS in July 2023, potentially accelerating its pathway to market and offering a new treatment option.
Syneron Medical Ltd. (Israel): Launched its new ePuls DermaFrac device in September 2023, which could potentially be used for facial rejuvenation procedures alongside HFS treatment, targeting a wider market segment.
Cleveland Clinic (US): Published research in September 2023 exploring the use of deep brain stimulation for HFS treatment, showcasing ongoing research into alternative and potentially more durable solutions.
List of Hemifacial Spasm Key companies in the market:
- Abbott
- Allergan, Inc.
- Cephalon Inc.
- GlaxoSmithKline plc
- Ipsen Group
- Johnson & Johnson Services, Inc.
- Medytox,Inc.
- Merz Pharma GmbH and Co. KGaA
- Novartis AG
- Pfizer